biotech.today

Details

  • ●Modalities: proteins, therapeutic enzymes
  • ●Therapeutic areas: Undisclosed
  • ●Key targets:
  • ●Indications: Undisclosed
  • ●Funding: $142M

Partners & investors

  • Lux Capital· Investor
  • NVIDIA· Investor

Key considerations

  • ●AI tools in use: ESM-2, ESMFold, ESM3
  • ●$142M seed (2024) including Nvidia, Lux Capital, Amazon
  • ●ESM3 Science 2025 paper
  • ●Apache 2.0 smaller ESM3 models
Get live updates on EvolutionaryScale’s hiring, filings, and partnerships. Follow in BT Pro →
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)

Key people

Alexander Rives

Co-Founder & Chief Scientist

protein-language-modelsesm
Visit website →LinkedIn →